ligand uk development limited
ligand uk development limited Company Information
Company Number
02600483
Next Accounts
172 days late
Shareholders
ligand holdings uk limited
Group Structure
View All
Industry
Manufacture of pharmaceutical preparations
+2Registered Address
suite 1, 7th floor 50 broadway, london, SW1H 0DB
Website
www.vernalis-research.comligand uk development limited Estimated Valuation
Pomanda estimates the enterprise value of LIGAND UK DEVELOPMENT LIMITED at £8.9m based on a Turnover of £3.8m and 2.31x industry multiple (adjusted for size and gross margin).
ligand uk development limited Estimated Valuation
Pomanda estimates the enterprise value of LIGAND UK DEVELOPMENT LIMITED at £64.7m based on an EBITDA of £6.7m and a 9.59x industry multiple (adjusted for size and gross margin).
ligand uk development limited Estimated Valuation
Pomanda estimates the enterprise value of LIGAND UK DEVELOPMENT LIMITED at £0 based on Net Assets of £-21.7m and 1.84x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Ligand Uk Development Limited Overview
Ligand Uk Development Limited is a live company located in london, SW1H 0DB with a Companies House number of 02600483. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in April 1991, it's largest shareholder is ligand holdings uk limited with a 100% stake. Ligand Uk Development Limited is a mature, small sized company, Pomanda has estimated its turnover at £3.8m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Ligand Uk Development Limited Health Check
Pomanda's financial health check has awarded Ligand Uk Development Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 4 areas for improvement. Company Health Check FAQs
3 Strong
0 Regular
4 Weak
Size
annual sales of £3.8m, make it smaller than the average company (£21.7m)
£3.8m - Ligand Uk Development Limited
£21.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 13%, show it is growing at a faster rate (7%)
13% - Ligand Uk Development Limited
7% - Industry AVG
Production
with a gross margin of 95.6%, this company has a lower cost of product (41.7%)
95.6% - Ligand Uk Development Limited
41.7% - Industry AVG
Profitability
an operating margin of 150.6% make it more profitable than the average company (3.9%)
150.6% - Ligand Uk Development Limited
3.9% - Industry AVG
Employees
with 17 employees, this is below the industry average (97)
- Ligand Uk Development Limited
97 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Ligand Uk Development Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £226.2k, this is less efficient (£298.6k)
- Ligand Uk Development Limited
£298.6k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Ligand Uk Development Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Ligand Uk Development Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Ligand Uk Development Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Ligand Uk Development Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 352.1%, this is a higher level of debt than the average (47.7%)
352.1% - Ligand Uk Development Limited
47.7% - Industry AVG
LIGAND UK DEVELOPMENT LIMITED financials
Ligand Uk Development Limited's latest turnover from December 2022 is £3.8 million and the company has net assets of -£21.7 million. According to their latest financial statements, we estimate that Ligand Uk Development Limited has 17 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 3,846,000 | 1,106,000 | 32,000 | 2,681,000 | 2,789,000 | 4,252,000 | 2,921,000 | 6,845,000 | 6,928,000 | 5,933,000 | 6,641,000 | 7,300,000 | 7,660,000 |
| Other Income Or Grants | |||||||||||||
| Cost Of Sales | 170,000 | 8,000 | 302,000 | 223,000 | 354,000 | 276,000 | 1,272,000 | 2,243,000 | 1,815,000 | 2,017,000 | 2,374,000 | 2,224,000 | |
| Gross Profit | 3,676,000 | 1,106,000 | 24,000 | 2,379,000 | 2,566,000 | 3,898,000 | 2,645,000 | 5,573,000 | 4,685,000 | 4,118,000 | 4,624,000 | 4,926,000 | 5,436,000 |
| Admin Expenses | 166,000 | 16,000 | 292,000 | 449,000 | 303,000 | 548,000 | 352,000 | 502,000 | 482,000 | 542,000 | 566,000 | ||
| Operating Profit | -142,000 | 2,363,000 | 2,274,000 | 3,449,000 | 2,342,000 | 5,025,000 | 4,333,000 | 3,616,000 | 4,142,000 | 4,384,000 | 4,870,000 | ||
| Interest Payable | 15,000 | 4,000 | 1,000 | 1,000 | 7,567,000 | 5,515,000 | |||||||
| Interest Receivable | 50,000 | 26,000 | 2,000 | ||||||||||
| Pre-Tax Profit | 2,367,000 | -361,000 | -142,000 | 2,348,000 | 2,320,000 | 3,474,000 | 2,365,000 | 5,027,000 | 4,330,000 | 3,594,000 | 4,147,000 | -3,410,000 | 966,000 |
| Tax | -433,000 | 90,000 | 343,000 | -3,000 | |||||||||
| Profit After Tax | 2,367,000 | -361,000 | -142,000 | 1,915,000 | 2,410,000 | 3,817,000 | 2,365,000 | 5,027,000 | 4,330,000 | 3,594,000 | 4,147,000 | -3,410,000 | 963,000 |
| Dividends Paid | |||||||||||||
| Retained Profit | 2,367,000 | -361,000 | -142,000 | 1,915,000 | 2,410,000 | 3,817,000 | 2,365,000 | 5,027,000 | 4,330,000 | 3,594,000 | 4,147,000 | -3,410,000 | 963,000 |
| Employee Costs | |||||||||||||
| Number Of Employees | |||||||||||||
| EBITDA* | 15,000 | 2,363,000 | 2,274,000 | 3,449,000 | 2,342,000 | 5,587,000 | 5,682,000 | 4,965,000 | 5,491,000 | 5,733,000 | 8,332,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 879,000 | 433,000 | 343,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |||
| Intangible Assets | 4,422,000 | 5,378,000 | 6,334,000 | 562,000 | 1,911,000 | 3,260,000 | 4,609,000 | 5,958,000 | |||||
| Investments & Other | 2,872,000 | 879,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||
| Debtors (Due After 1 year) | 1,290,000 | ||||||||||||
| Total Fixed Assets | 8,584,000 | 6,257,000 | 6,334,000 | 433,000 | 343,000 | 1,000 | 1,000 | 563,000 | 1,912,000 | 3,261,000 | 4,610,000 | 5,959,000 | |
| Stock & work in progress | 265,000 | 77,000 | 130,000 | 250,000 | 505,000 | 308,000 | 511,000 | ||||||
| Trade Debtors | 40,000 | 111,000 | 1,337,000 | 1,381,000 | 1,434,000 | 1,456,000 | 1,824,000 | 1,829,000 | 2,197,000 | 2,502,000 | 2,214,000 | ||
| Group Debtors | |||||||||||||
| Misc Debtors | 16,000 | 61,000 | 41,000 | 22,000 | 54,000 | 44,000 | 94,000 | 31,000 | 282,000 | ||||
| Cash | 19,000 | 7,000 | 188,000 | 81,000 | 23,000 | 21,000 | 4,000 | 137,000 | 1,000 | 1,000 | |||
| misc current assets | |||||||||||||
| total current assets | 16,000 | 40,000 | 111,000 | 80,000 | 1,609,000 | 1,610,000 | 1,592,000 | 1,501,000 | 2,029,000 | 2,127,000 | 2,933,000 | 2,842,000 | 3,008,000 |
| total assets | 8,600,000 | 6,297,000 | 6,445,000 | 80,000 | 2,042,000 | 1,953,000 | 1,593,000 | 1,502,000 | 2,592,000 | 4,039,000 | 6,194,000 | 7,452,000 | 8,967,000 |
| Bank overdraft | |||||||||||||
| Bank loan | |||||||||||||
| Trade Creditors | 2,000 | 6,000 | 5,000 | 9,000 | 278,000 | 26,000 | 126,000 | ||||||
| Group/Directors Accounts | |||||||||||||
| other short term finances | 886,000 | ||||||||||||
| hp & lease commitments | |||||||||||||
| other current liabilities | 173,000 | 24,000 | 23,000 | 7,000 | 73,000 | 135,000 | 93,000 | 32,000 | 95,000 | 115,000 | 53,049,000 | 58,028,000 | 391,000 |
| total current liabilities | 173,000 | 24,000 | 23,000 | 7,000 | 75,000 | 141,000 | 98,000 | 41,000 | 373,000 | 141,000 | 53,049,000 | 58,028,000 | 1,403,000 |
| loans | 30,106,000 | 30,319,000 | 70,496,000 | ||||||||||
| hp & lease commitments | |||||||||||||
| Accruals and Deferred Income | 9,000 | 108,000 | 492,000 | 51,000 | |||||||||
| other liabilities | 30,107,000 | 23,616,000 | 27,425,000 | 29,680,000 | 33,180,000 | 35,511,000 | 41,296,000 | 47,296,000 | 38,000 | 80,000 | |||
| provisions | |||||||||||||
| total long term liabilities | 30,106,000 | 30,319,000 | 30,107,000 | 23,616,000 | 27,425,000 | 29,680,000 | 33,180,000 | 35,511,000 | 41,296,000 | 47,305,000 | 146,000 | 572,000 | 56,457,000 |
| total liabilities | 30,279,000 | 30,343,000 | 30,130,000 | 23,623,000 | 27,500,000 | 29,821,000 | 33,278,000 | 35,552,000 | 41,669,000 | 47,446,000 | 53,195,000 | 58,600,000 | 57,860,000 |
| net assets | -21,679,000 | -24,046,000 | -23,685,000 | -23,543,000 | -25,458,000 | -27,868,000 | -31,685,000 | -34,050,000 | -39,077,000 | -43,407,000 | -47,001,000 | -51,148,000 | -48,893,000 |
| total shareholders funds | -21,679,000 | -24,046,000 | -23,685,000 | -23,543,000 | -25,458,000 | -27,868,000 | -31,685,000 | -34,050,000 | -39,077,000 | -43,407,000 | -47,001,000 | -51,148,000 | -48,893,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Operating Profit | -142,000 | 2,363,000 | 2,274,000 | 3,449,000 | 2,342,000 | 5,025,000 | 4,333,000 | 3,616,000 | 4,142,000 | 4,384,000 | 4,870,000 | ||
| Depreciation | |||||||||||||
| Amortisation | 956,000 | 157,000 | 562,000 | 1,349,000 | 1,349,000 | 1,349,000 | 1,349,000 | 3,462,000 | |||||
| Tax | -433,000 | 90,000 | 343,000 | -3,000 | |||||||||
| Stock | -265,000 | 265,000 | -77,000 | 77,000 | -120,000 | -255,000 | 197,000 | -203,000 | 511,000 | ||||
| Debtors | 1,266,000 | -71,000 | 50,000 | -1,276,000 | -85,000 | -12,000 | -44,000 | 1,478,000 | 5,000 | -418,000 | -242,000 | 37,000 | 2,496,000 |
| Creditors | -2,000 | -4,000 | 1,000 | -4,000 | 9,000 | 252,000 | 26,000 | -126,000 | 126,000 | ||||
| Accruals and Deferred Income | 149,000 | 1,000 | 16,000 | -66,000 | -62,000 | 42,000 | 61,000 | 32,000 | -29,000 | -53,033,000 | -5,363,000 | 58,078,000 | 442,000 |
| Deferred Taxes & Provisions | |||||||||||||
| Cash flow from operations | -19,000 | 3,403,000 | 2,118,000 | 3,924,000 | 2,366,000 | 4,150,000 | 6,020,000 | -47,369,000 | 173,000 | 63,851,000 | 5,890,000 | ||
| Investing Activities | |||||||||||||
| capital expenditure | |||||||||||||
| Change in Investments | 1,993,000 | 879,000 | -1,000 | 1,000 | 1,000 | ||||||||
| cash flow from investments | |||||||||||||
| Financing Activities | |||||||||||||
| Bank loans | |||||||||||||
| Group/Directors Accounts | |||||||||||||
| Other Short Term Loans | -886,000 | 886,000 | |||||||||||
| Long term loans | -213,000 | 30,319,000 | -70,496,000 | 70,496,000 | |||||||||
| Hire Purchase and Lease Commitments | |||||||||||||
| other long term liabilities | -30,107,000 | 6,491,000 | -3,809,000 | -2,255,000 | -3,500,000 | -2,331,000 | 35,511,000 | -6,000,000 | 47,258,000 | -42,000 | 80,000 | ||
| share issue | |||||||||||||
| interest | -15,000 | 46,000 | 25,000 | -1,000 | -7,565,000 | -5,515,000 | |||||||
| cash flow from financing | -213,000 | 212,000 | 6,491,000 | -3,824,000 | -2,209,000 | -3,475,000 | -2,332,000 | -3,566,000 | -6,000,000 | 47,258,000 | -42,000 | -77,712,000 | 16,011,000 |
| cash and cash equivalents | |||||||||||||
| cash | -19,000 | 12,000 | -181,000 | 107,000 | 58,000 | 23,000 | 17,000 | -133,000 | 136,000 | 1,000 | |||
| overdraft | |||||||||||||
| change in cash | -19,000 | 12,000 | -181,000 | 107,000 | 58,000 | 23,000 | 17,000 | -133,000 | 136,000 | 1,000 |
ligand uk development limited Credit Report and Business Information
Ligand Uk Development Limited Competitor Analysis
Perform a competitor analysis for ligand uk development limited by selecting its closest rivals, whether from the MANUFACTURING sector, other small companies, companies in SW1H area or any other competitors across 12 key performance metrics.
ligand uk development limited Ownership
LIGAND UK DEVELOPMENT LIMITED group structure
Ligand Uk Development Limited has no subsidiary companies.
Ultimate parent company
LIGAND PHARMACEUTICALS INC
#0112087
2 parents
LIGAND UK DEVELOPMENT LIMITED
02600483
ligand uk development limited directors
Ligand Uk Development Limited currently has 4 directors. The longest serving directors include Mr Matthew Korenberg (Oct 2018) and Mr Andrew Reardon (Nov 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Matthew Korenberg | United Kingdom | 50 years | Oct 2018 | - | Director |
| Mr Andrew Reardon | United Kingdom | 50 years | Nov 2022 | - | Director |
| Octavio Espinoza | United Kingdom | 54 years | Nov 2022 | - | Director |
| Mr Todd Davis | United Kingdom | 64 years | Dec 2022 | - | Director |
P&L
December 2022turnover
3.8m
+248%
operating profit
5.8m
0%
gross margin
95.6%
-4.42%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
-21.7m
-0.1%
total assets
8.6m
+0.37%
cash
0
0%
net assets
Total assets minus all liabilities
ligand uk development limited company details
company number
02600483
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
21200 - Manufacture of pharmaceutical preparations
72110 - Research and experimental development on biotechnology
incorporation date
April 1991
age
34
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2022
previous names
vernalis development limited (December 2020)
vernalis development limited (October 2009)
See moreaccountant
-
auditor
GRANT THORNTON UK LLP
address
suite 1, 7th floor 50 broadway, london, SW1H 0DB
Bank
BARCLAYS BANK PLC, BARCLAYS BANK PLC
Legal Advisor
-
ligand uk development limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 5 charges/mortgages relating to ligand uk development limited. Currently there are 0 open charges and 5 have been satisfied in the past.
ligand uk development limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for LIGAND UK DEVELOPMENT LIMITED. This can take several minutes, an email will notify you when this has completed.
ligand uk development limited Companies House Filings - See Documents
| date | description | view/download |
|---|
